Wedbush Issues Positive Forecast for Maze Therapeutics (NASDAQ:MAZE) Stock Price

Maze Therapeutics (NASDAQ:MAZE) had its target price upped by equities researchers at Wedbush from $35.00 to $36.00 in a report released on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 28.16% from the company’s current price.

Several other equities analysts have also recently issued reports on the stock. Guggenheim lifted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. JPMorgan Chase & Co. increased their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, BTIG Research boosted their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $37.00.

Maze Therapeutics Stock Down 5.2%

MAZE stock traded down $1.54 during trading on Friday, reaching $28.09. 78,871 shares of the company’s stock were exchanged, compared to its average volume of 299,937. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $34.29. The firm has a market cap of $1.23 billion and a PE ratio of -1.39. The company’s fifty day moving average price is $25.57 and its 200-day moving average price is $17.07.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insiders Place Their Bets

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its position in Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after purchasing an additional 1,455 shares during the last quarter. CWM LLC bought a new position in Maze Therapeutics during the second quarter valued at about $28,000. New York State Common Retirement Fund acquired a new position in Maze Therapeutics in the 1st quarter valued at approximately $25,000. Legal & General Group Plc lifted its position in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after acquiring an additional 3,371 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Maze Therapeutics by 80.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,890 shares of the company’s stock worth $205,000 after purchasing an additional 3,524 shares in the last quarter.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.